First Trust US Equity Income logo

First Trust US Equity Income (UINDl)

Market Closed
CBOE CBOE
- Market Cap
0.4% Div Yield
- Volume
Want to track UINDl and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

UINDl pays dividends to its shareholders, with the most recent payment made on Jun 30, 2026. The next estimated payment will be in In 1 month on Sep 30, 2026 for a total of $0.2978.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on LSE (USD).

First Trust US Equity Income (UINDl) FAQ

On which exchange is it traded?

First Trust US Equity Income is listed on CBOE.

What is its stock symbol?

The ticker symbol is UINDl.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.4%.

What is its market cap?

As of today, no market cap data is available.

Has First Trust US Equity Income ever had a stock split?

No, there has never been a stock split.

First Trust US Equity Income Profile

CBOE Exchange
CN Country

Overview

China Resources Double-Crane Pharmaceutical Co.,Ltd., established in 1939 and headquartered in Beijing, is a prominent player in the pharmaceutical industry within the People's Republic of China. As a subsidiary under Beijing Pharmaceutical Group Co., Ltd., the company has carved out a significant presence, focusing on the development, production, and sale of a varied range of pharmaceutical products. Its dedication to healthcare and medicine is reflected in its broad offering of pharmaceutical solutions designed to meet diverse medical needs.

Products and Services

The company's extensive portfolio spans various therapeutic areas, showcasing their commitment to addressing a wide array of health concerns:

  • Blood Pressure: A range of pharmaceutical products aimed at managing and treating hypertension, ensuring patients have access to effective medications for controlling high blood pressure.
  • Blood Sugar: Dedicated solutions for the effective control and management of diabetes, offering patients a means to manage their blood sugar levels through medication.
  • Injection: A variety of injectable medications for different medical uses, including emergency care, chronic conditions, and treatments requiring direct delivery into the bloodstream.
  • Lipid-lowering: Medications designed to help reduce cholesterol levels, contributing to the prevention of cardiovascular diseases and promoting heart health.
  • Pediatrics: Specialized pharmaceutical products targeted at addressing the health needs of infants, children, and adolescents, ensuring age-appropriate treatments across a range of pediatric conditions.
  • Nephrology: A spectrum of products focused on kidney health and the treatment of renal diseases, supporting patients in managing their kidney-related conditions effectively.
  • API: Active Pharmaceutical Ingredients (API), which are crucial in the production of various medications, ensuring high-quality components for pharmaceutical manufacturing.
  • Pharmaceutical: A broad category that includes a wide range of medications and health care products beyond the specific areas mentioned, catering to the overall well-being and specific medical needs of patients.
  • Other: A miscellaneous category that encompasses products and services not explicitly listed, indicating the company's versatility and commitment to addressing emerging health concerns.

Contact Information

Address: No. 1, Lize East 2nd Road, Beijing, China, 100102
Phone: 86 10 6474 2227